Royalty Report: Cannabis, Drugs, Therapeutic – Collection: 269589

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Cannabis
  • Drugs
  • Therapeutic
  • Delivery
  • Medical
  • Pain
  • Technical Know How

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 269589

License Grant
The Israeli Licensor, the technology transfer company of the University, hereby grants the Israel Company an option to receive an exclusive, sublicensable, worldwide royalty-bearing license to Licensors interest in the Study Results in the field of Systemic and local, tran-dermal and trans-mucosal delivery of cannabinoids using Exudates based formulations.
License Property
The Feasibility Study Program relates to the development of a Cannabis patch and can the prospect of the cannabis patch be considered a platform, depending on its composition and the character of the ingredients included within it.
Field of Use
This agreement pertains to the drug industry relating to Cannabis.

IPSCIO Record ID: 231940

License Grant
License Agreement terms are worldwide royalty-bearing license to the Israeli University Study Results in the field of production of powders from Cannabinoid oil, upon the commercial terms  and other terms and conditions set forth in a license agreement to be finally negotiated between the Israeli Parties.
License Property
The aim of this study is to evaluate the possibility to convert the cannabis oil into a powder form. This will be achieved by making an oil-in-water emulsions, in presence of polymers and/or small molecules dissolved in the continuous phase of the emulsion.
Field of Use
Should the Israeli Licensee exercise the Option in a timely manner, the Licensee shall be responsible for ongoing costs in connection with the filing, prosecution and maintenance of any patents arising from the Study Results.  After performing the feasibility study, if approved, the next R&D project will be tailoring the technology for specific applications such as oral or nasal delivery system.

IPSCIO Record ID: 249613

License Grant
The Canadian Licensor and Licensee have agreed to collaborate to develop and manufacture a line of at least 3 co-branded topical cosmetic products formulated with a cannabinoid or cannabinoids.
License Property
Cannabis is a plant used in products for medical proposes.
Field of Use
This agreement pertains to the drug industry relating to cannabis.

IPSCIO Record ID: 305318

License Grant
The agreement provides for the Licensor’s grant of a non-exclusive right and sub-license to use certain Licensor technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa.

The term of the agreement ends the earlier of (i) July 15, 2020 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year.

License Property
The technology is for eluting patches.

Licensor has acquired an exclusive, worldwide license for an eluting transmucosal patch platform (ETP) for non-invasive drug delivery in the cannabis field.

Licensor is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems.

Field of Use
The Technology is centered around an eluting patch platform (“ETP”), which is a bio adhesive, transmucosal orally dissolving thin film system. The platform allows for actives loaded onto the ETP to be absorbed by the buccal mucosa into the body.

The license is for transmucosal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids.

Licensor’s oral patch has been shown in clinical studies to be a safe, accurate and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability.
The OralTabs product contains 21mg of full spectrum CBD in each tab and is available in 5 and 30 pack boxes in a wild mint berry flavor with additional packet sizes, formulations and flavors planned for later on in the year.

With concern growing over vaping and the numerous incidents now being reported, Licensee’s oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles.  Licensee is dedicated to the production, research, cultivation, processing and distribution of medicinal cannabis oil to pharmaceutical companies worldwide.

IPSCIO Record ID: 255048

License Grant
The Israeli Licensee entered into an exclusive, worldwide, sublicensable, royalty-bearing license with the Israeli Licensor, the technology transfer company of the University, for license to make commercial use of the licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell Products, all within the field of cannabinoid technology and delivery.
License Property
Cannabinoid technology.
Field of Use
The Israeli Licensee business is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals and advanced drug delivery projects.

IPSCIO Record ID: 249612

License Grant
The Canadian Licensor and Canadian Licensee have agreed to collaborate to develop and manufacture a line of at least 3 co-branded topical cosmetic products formulated with a cannabinoid or cannabinoids.
License Property
Cannabis is a plant used in products for medical proposes.
Field of Use
This agreement pertains to the drug industry relating to cosmetic products.

IPSCIO Record ID: 241951

License Grant
Canadian Licensor hereby grants to Israeli Licensee an exclusive license to exploit the Licensor solely as necessary to develop, manufacture, market, use, sell, offer for sale, import, export, commercialize and distribute the Licensed Products (the License).
License Property
Licensed Product relates to an orally dissolved film containing CBD, as an active material, for medical treatment.

Licensed Product shall mean Licensor’s patch described below hereto in combination with Cannabidiol (CBD) for medical or recreational cannabis, where latter permitted for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted (other than in the field of oral care) or any other product exploiting the Licensee Cannabis IP for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted.

Description of Patch – A “Eluting Transmucosal Patch Platform (ETP)” for non-invasive drug delivery.

Licensor Patents shall mean those patents and patent applications listed below, as well as patents issuing therefrom, and any substitutions, divisions, continuations, continuations-in-part (but only to the extent that they cover the same invention claimed in the foregoing), reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like, and any provisional applications, of any such patents or patent applications.

Patent(s)/Patent Application(s)
1. WO 2012/104834 A1
New oral dissolving films for insulin administration, for treating diabetes.
filed on December 2011. National Phase at Israel and the USA.
2. WO 2010/135053 A2
Dual and single layer dosage forms.
Issued USA patent on April 28, 2015.
3. PCT/IL 2017/050845
Adhesive Oral dissolved Films in Managing Oral Care.
PCT on 31 July 2017.

Field of Use
This agreement pertains to the drug industry relating to Cannabis.

IPSCIO Record ID: 236901

License Grant
The Israeli Licensor, the technology transfer company of the University, hereby grants the Israeli Company an exclusive license to make commercial use of the Licensed Technology, in order to develop, manufacture, market, distribute or sell a Product, all within the Field and the Territory only, subject to and in accordance with the terms and conditions of this Agreement.
License Property
The Patent application pertains to the technology of Powder Formulation of Cannaboid Oil.
Field of Use
Field shall mean Powder Formulation of Cannaboid Oil.  Powdered cannabis may be the next big breakthrough for medical marijuana patients who do not want to smoke.

IPSCIO Record ID: 265496

License Grant
The Canadian Company obtained an exclusive licence to exploit exclusive varieties of cannabis and access to extensive data that Licensor had gathered from thousands of its patients for over a decade.
License Property
Licensor is a research and development-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis.
Field of Use
This agreement pertains to the drug industry relating to the cannabis market.

IPSCIO Record ID: 359060

License Grant
The Parties entered into a sponsored research agreement to conduct research and development efforts relating to Licensors COVID-19 and rheumatoid arthritis (RA) product candidates. The focused is on characterizing the activity of cannabinoids in RA and in hyperinflammatory syndrome related to COVID-19.

In accordance with the terms of the Research Agreement, Israelis Licensee and Israelis Licensor will have joint ownership of any IP created as a result of research programs covered by such agreement. In connection with the Research Agreement, Licensor agreed not to work, study or develop any technologies with other entities that compete with our work with Licensor for our COVID-19 product candidate or RA product candidate for a term of three and seven years, respectively, from the end of the parties’ collaboration with respect to the COVID-19 product candidate and seven years from the end of the term of the Research Agreement with respect to the RA product candidate.

License Property
Cannabidiol, or CBD, oil is derived from CBD strains with low levels of Tetrahydrocannabinol, or THC. The discovery platform currently focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient, or API, for our RA product candidate and COVID-19 product candidate.

The Licensor  have been conducting research on the use of cannabis to treat disorders with widespread inflammatory responses, such as RA and COVID-19. Parties hope that by decoding the cannabinoid mechanism of action during inflammatory storms, the Parties can treat inflammation associated with COVID-19 where conventional drugs and other therapies have failed.

Field of Use
Field of use is for the treatment in RA and in hyperinflammatory syndrome related to COVID-19.

Rheumatoid arthritis (RA) is a long-term autoimmune disorder. COVID-19 is a virus infection.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.